Evidence map›Paper›PMID 36179670›Full record

ArticleCell2022

Pan-cancer analyses reveal cancer-type-specific fungal ecologies and bacteriome interactions.

Lian Narunsky-Haziza, Gregory D Sepich-Poore, Ilana Livyatan, Omer Asraf, Cameron Martino, Deborah Nejman, Nancy Gavert, Jason E Stajich, Guy Amit, Antonio González and 16 more

Registry-linked trialAbstract read
In one paragraph

Article in Cell, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07783971 (Study on the Microbial Environment of Non-small Cell Lung Cancer Based on Mycogenomics and Its Clinical Relevance), which is not on this map. Cited by 336 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
336citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07783971 recruitingnot on this mapstarted 2026, after this paper: background citation

Study on the Microbial Environment of Non-small Cell Lung Cancer Based on Mycogenomics and Its Clinical Relevance

TypeobservationalSponsor958th Army Hospital of the Chinese People's Liberation ArmyRan2026 to 2028Enrolled10ConditionsFungal Diseases, Lung Cancer (NSCLC), Microbioata
3 · Its place in the literature

Who cites it

336 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review

276 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors.

Lian Narunsky-HazizaDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel; Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel.
Gregory D Sepich-PooreDepartment of Bioengineering, University of California San Diego, La Jolla, CA, USA; Micronoma Inc., San Diego, CA, USA.
Ilana LivyatanDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel; Department of Computer Science and Applied Mathematics, Weizmann Institute of Science, Rehovot, Israel.
Omer AsrafDepartment of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel.
Cameron MartinoBioinformatics and Systems Biology Program, University of California, San Diego, La Jolla, CA, USA; Center for Microbiome Innovation, University of California San Diego, La Jolla, CA, USA; Department of Pediatrics, University of California San Diego School of Medicine, La Jolla, CA, USA.
Deborah NejmanDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
Nancy GavertDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
Jason E StajichDepartment of Microbiology and Plant Pathology, Institute for Integrative Genome Biology, University of California Riverside, Riverside, CA, USA.
Guy AmitDepartment of Physics, Bar-Ilan University, Ramat-Gan, Israel; Department of Natural Sciences, The Open University of Israel, Raanana, Israel.
Antonio GonzálezDepartment of Pediatrics, University of California San Diego School of Medicine, La Jolla, CA, USA.
Stephen WandroMicronoma Inc., San Diego, CA, USA.
Gili PerryDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel; Cancer Research Center, Sheba Medical Center, Ramat Gan, Israel; Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Ruthie ArielDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
Arnon MeltserDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
Justin P ShafferDepartment of Pediatrics, University of California San Diego School of Medicine, La Jolla, CA, USA.
Qiyun ZhuSchool of Life Sciences, Arizona State University, Tempe, AZ, USA; Biodesign Center for Fundamental and Applied Microbiomics, Arizona State University, Tempe, AZ, USA.
Nora Balint-LahatSackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; Department of Pathology, Sheba Medical Center, Ramat Gan, Israel.
Iris BarshackSackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; Department of Pathology, Sheba Medical Center, Ramat Gan, Israel.
Maya DadianiCancer Research Center, Sheba Medical Center, Ramat Gan, Israel.
Einav N Gal-YamBreast Oncology Institute, Sheba Medical Center, Ramat Gan, Israel.
Sandip Pravin PatelCenter for Microbiome Innovation, University of California San Diego, La Jolla, CA, USA; Moores Cancer Center, University of California San Diego Health, La Jolla, CA, USA.
Amir BashanDepartment of Physics, Bar-Ilan University, Ramat-Gan, Israel.
Austin D SwaffordCenter for Microbiome Innovation, University of California San Diego, La Jolla, CA, USA.
Yitzhak PilpelDepartment of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel.
Rob KnightDepartment of Bioengineering, University of California San Diego, La Jolla, CA, USA; Center for Microbiome Innovation, University of California San Diego, La Jolla, CA, USA; Department of Pediatrics, University of California San Diego School of Medicine, La Jolla, CA, USA; Department of Computer Science and Engineering, University of California San Diego, La Jolla, CA, USA. Electronic address: robknight@eng.ucsd.edu.
Ravid StraussmanDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel. Electronic address: ravidst@weizmann.ac.il.

Funding

STRUCTURAL NEUROIMAGING COREP30MH062512 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jennifer E Iudicello · 2001 to 2026
$50.4M
Translational Methamphetamine AIDS Research Center (TMARC)P50DA026306 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GRANT, IGOR · 2009 to 2018
$33.9M
UCSD/SDSU IRACDAK12GM068524 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TREJO, JOANN · 2003 to 2025
$24.4M
NEUROMOTORP01DA012065 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LETENDRE, SCOTT L · 1999 to 2009
$17.8M
The UCSD Microbiome and Metagenomics Center (Summit Supplement)U24DK131617 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jack Anthony Gilbert, ROB KNIGHT · 2022 to 2026
$15.3M
Mapping host-microbe-metabolite interactions in 3D to find diet-derived enhancers of immunityDP1AT010885 · NCCIH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KNIGHT, ROB · 2019 to 2023
$5.5M
Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)U24CA248454 · NCI · NORTHERN ARIZONA UNIVERSITY · PI CAPORASO, JAMES GREGORY · 2020 to 2024
$3.7M
COMT Genotype and Risky Decision Making in HIV and Methamphetamine DependenceR01DA026334 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHERNER, MARIANA · 2009 to 2010
$1.1M
Impact of Alcohol Use and HIV Infection on Brain Connectivity AbnormalitiesR00AA020235 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GONGVATANA, ASSAWIN · 2013 to 2015
$732k
Comprehensive characterization of the cancer microbiome and its immuno-oncology interfaceF30CA243480 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI POORE, GREGORY DERRICK · 2020 to 2021
$73k
NCCIH NIH HHS DP1 AT010885NCI NIH HHS F30 CA243480NCI NIH HHS HHSN261201400008CNCI NIH HHS HHSN261201500003CNCI NIH HHS HHSN261201500003INCI NIH HHS U24 CA248454NIAAA NIH HHS R00 AA020235NIDA NIH HHS P01 DA012065NIDA NIH HHS P50 DA026306NIDA NIH HHS R01 DA026334NIDDK NIH HHS U24 DK131617NIGMS NIH HHS K12 GM068524NIMH NIH HHS P30 MH062512
6 · The paper itself

Abstract

Cancer-microbe associations have been explored for centuries, but cancer-associated fungi have rarely been examined. Here, we comprehensively characterize the cancer mycobiome within 17,401 patient tissue, blood, and plasma samples across 35 cancer types in four independent cohorts. We report fungal DNA and cells at low abundances across many major human cancers, with differences in community compositions that differ among cancer types, even when accounting for technical background. Fungal histological staining of tissue microarrays supported intratumoral presence and frequent spatial association with cancer cells and macrophages. Comparing intratumoral fungal communities with matched bacteriomes and immunomes revealed co-occurring bi-domain ecologies, often with permissive, rather than competitive, microenvironments and distinct immune responses. Clinically focused assessments suggested prognostic and diagnostic capacities of the tissue and plasma mycobiomes, even in stage I cancers, and synergistic predictive performance with bacteriomes.

Indexed as

MycobiomeNeoplasmsDNA, FungalFungiHumansDNA, Fungalbiomarkerscancerfungiliquid biopsymetagenomicsmetatranscriptomicsmicrobial interactionstumor microbiometumor mycobiome

Identifiers

PMID36179670
PMCPMC9567272

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.